US Stock MarketDetailed Quotes
OTLK Outlook Therapeutics
- 2.050
- +0.350+20.59%
Close Nov 29 13:00 ET
- 2.030
- -0.020-0.98%
Post 17:01 ET
48.49MMarket Cap-348P/E (TTM)
2.090High1.690Low7.85MVolume1.700Open1.700Pre Close14.80MTurnover56.29%Turnover RatioLossP/E (Static)23.66MShares12.85052wk High-0.58P/B28.58MFloat Cap0.87052wk Low--Dividend TTM13.94MShs Float219.200Historical High--Div YieldTTM23.54%Amplitude0.870Historical Low1.885Avg Price1Lot Size
Outlook Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Jun 30, 2024 | (Q2)Mar 31, 2024 | (Q1)Dec 31, 2023 | (FY)Sep 30, 2023 | (Q4)Sep 30, 2023 | (Q3)Jun 30, 2023 | (Q2)Mar 31, 2023 | (Q1)Dec 31, 2022 | (FY)Sep 30, 2022 | (Q4)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -47.64%-19.51M | -137.44%-19.27M | -46.41%-13.03M | 24.18%-42.97M | -24.30%-12.74M | 37.36%-13.22M | 43.39%-8.11M | 19.01%-8.9M | -4.46%-56.67M | -14.02%-10.25M |
| Net income from continuing operations | 314.80%44.41M | -1,617.52%-114.29M | 40.10%-11.18M | 10.70%-58.98M | 9.44%-12.99M | -17.87%-20.68M | 66.23%-6.65M | -29.04%-18.66M | -24.24%-66.05M | -7.02%-14.35M |
| Operating gains losses | -295,839.99%-56M | 5,075,432.12%83.74M | -90.34%50.79K | -11.61%537.74K | -37.62%-5.44K | 108.69%18.94K | -105.31%-1.65K | -34.19%525.89K | 22.04%608.35K | 98.68%-3.96K |
| Depreciation and amortization | 156.18%28.67K | 156.29%28.2K | 161.60%28.2K | -78.41%44.19K | -78.21%11.22K | -78.17%11.19K | -78.47%11K | -78.81%10.78K | -21.91%204.69K | 1.57%51.47K |
| Other non cash items | --0 | --1.69M | -27.58%993K | 102.00%5.13M | 724.33%3.76M | --0 | --0 | 170.42%1.37M | 643.16%2.54M | 79.62%455.64K |
| Change In working capital | -156.72%-1.78M | 55.84%-1.26M | -164.98%-4.2M | 382.19%4.75M | -189.78%-1.99M | 156.28%3.14M | -474.19%-2.86M | 608.97%6.46M | 76.21%-1.68M | -26.30%2.22M |
| -Change in prepaid assets | -2,764.49%-3.04M | -595.95%-524.12K | -410.12%-2.45M | 184.61%2.62M | 30.80%1.79M | 103.38%113.96K | 90.67%-75.31K | 376.18%788.51K | -78.78%-3.09M | -73.56%1.37M |
| -Change in payables and accrued expense | -60.65%1.28M | 73.60%-731.16K | -130.84%-1.75M | 63.40%2.37M | -543.20%-3.8M | 248.51%3.26M | -275.18%-2.77M | 370.87%5.68M | 126.40%1.45M | 139.74%857.98K |
| -Change in other current assets | 90.11%-22.97K | ---- | ---- | ---208.2K | --24.02K | ---232.22K | ---- | ---- | --0 | --0 |
| -Change in other current liabilities | 43.50%-2.22K | --0 | --0 | 37.01%-27K | --0 | 63.94%-3.93K | -11.06%-11.64K | -11.27%-11.42K | 71.50%-42.85K | -11.26%-11.21K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -47.64%-19.51M | -137.44%-19.27M | -46.41%-13.03M | 24.18%-42.97M | -24.30%-12.74M | 37.36%-13.22M | 43.39%-8.11M | 19.01%-8.9M | -4.46%-56.67M | -14.02%-10.25M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | ||||||||||
| Cash from discontinued investing activities | ||||||||||
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 30.69%4.31M | 9,501.66%56.14M | -100.01%-3.18K | -17.83%48.97M | 49.08%2.42M | 129.16%3.3M | -122.90%-597.13K | -34.23%43.85M | 6.05%59.59M | -56.93%1.63M |
| Net issuance payments of debt | --0 | 62.48%-1.08K | -100.02%-3.18K | 952.41%19.77M | 45.79%-3.08K | 99.97%-2.98K | 99.06%-2.89K | 106.20%19.78M | -136.77%-2.32M | 71.17%-5.69K |
| Net common stock issuance | 30.57%4.31M | 16,647.34%56.14M | --0 | -51.81%30.02M | 48.75%2.43M | 1,025.98%3.3M | -112.44%-339.28K | -57.27%24.64M | 34.57%62.31M | -56.92%1.63M |
| Proceeds from stock option exercised by employees | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | -94.27%205.85K | --0 |
| Net other financing activities | ---- | ---- | ---- | -37.32%-823.89K | --0 | --0 | ---254.96K | 5.18%-568.93K | -7,370.12%-600K | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 30.69%4.31M | 9,501.66%56.14M | -100.01%-3.18K | -17.83%48.97M | 49.08%2.42M | 129.16%3.3M | -122.90%-597.13K | -34.23%43.85M | 6.05%59.59M | -56.93%1.63M |
| Net cash flow | ||||||||||
| Beginning cash position | 8.25%47.23M | -80.21%10.36M | 34.46%23.39M | 20.17%17.4M | 29.54%33.71M | -25.32%43.63M | -25.39%52.34M | 20.17%17.4M | 15.49%14.48M | 32.14%26.02M |
| Current changes in cash | -53.27%-15.2M | 523.25%36.87M | -137.30%-13.04M | 105.35%6M | -19.62%-10.32M | 69.39%-9.92M | 25.71%-8.71M | -37.23%34.94M | 50.39%2.92M | -65.39%-8.62M |
| End cash Position | -5.00%32.02M | 8.25%47.23M | -80.21%10.36M | 34.46%23.39M | 34.46%23.39M | 29.54%33.71M | -25.32%43.63M | -25.39%52.34M | 20.17%17.4M | 20.17%17.4M |
| Free cash flow | -47.64%-19.51M | -137.44%-19.27M | -46.41%-13.03M | 24.18%-42.97M | -24.30%-12.74M | 37.36%-13.22M | 43.39%-8.11M | 19.01%-8.9M | -4.46%-56.67M | -14.02%-10.25M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
